SCHEMBL104050

SCHEMBL104050

Nc1ncc(F)cc1F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29563062 1.00
Hydrochloric Acid SCHEMBL31514821 0.97 VRK1 (0.37)
SCHEMBL298068 0.80
SCHEMBL29966569 0.79
SCHEMBL1198418 0.79
SCHEMBL15688569 0.79
SCHEMBL30955011 0.78 VRK1 (0.40)
Hydrochloric Acid SCHEMBL26922125 0.77 HTT (0.34)
SCHEMBL23888674 0.75
SCHEMBL13190362 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 385 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025125665-A1 FURTHER SUBSTITUTED IMIDAZOLES AS INHIBITORS OF NAV1.8 Grünenthal GmbH (DE) 2025-06-19 WO claimed
WO-2025093624-A1 A PROCESS FOR PREPARING 3,5-DIFLUORO-2-PYRIDINECARBOXAMIDE INTERVET INTERNATIONAL B.V. (NL) 2025-05-08 WO claimed
WO-2025093631-A1 A PROCESS FOR PREPARING 2-AMINO-3,5-DIFLUOROPYRIDINE OR A SALT THEREOF INTERVET INTERNATIONAL B.V. (NL) 2025-05-08 WO claimed
EP-4743465-A1 BICYCLIC MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2026-05-20 EP disclosed
EP-4722205-A1 HETEROCYCLIC COMPOUND AND NOXIOUS ARTHROPOD-CONTROLLING COMPOSITION CONTAINING SAME Sumitomo Chemical Company, Limited (JP) 2026-04-08 EP disclosed
US-12595239-B2 Substituted isoxazoline derivatives BASF SE (DE) 2026-04-07 US disclosed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 EP disclosed
US-12565490-B2 Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2026-03-03 US disclosed
EP-4430042-B1 6-HETERO ARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS INC (US) 2026-02-18 EP disclosed
EP-4666856-A2 MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO Corteva Agriscience LLC (US) 2025-12-24 EP disclosed
US-7220863-B2 Process for preparing 2-aminopyridine derivatives KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2007-05-22 US disclosed
EP-1765795-A2 ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS Addex Pharmaceuticals SA (CH) 2007-03-28 EP disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 EP disclosed
US-20070015773-A1 Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders AMGEN INC. 2007-01-18 US disclosed
US-20070015773-A1 Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders AMGEN INC. 2007-01-18 US disclosed
WO-2007002701-A2 ANTI-INFLAMMATORY ARYL NITRILE COMPOUNDS AMGEN INC. (US) 2007-01-04 WO disclosed
WO-2007002701-A2 ANTI-INFLAMMATORY ARYL NITRILE COMPOUNDS AMGEN INC. (US) 2007-01-04 WO disclosed
US-20060047124-A1 Process for preparing 2-aminopyridine derivatives KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2006-03-02 US disclosed
WO-2005123703-A2 ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMACEUTICALS SA (CH) 2005-12-29 WO disclosed